Finance3 sources
Alnylam faces challenges with heart drug development
- Alnylam, once aiming to be a $100 billion biotech, is facing difficulties with its heart drug development.
- CRISPR Therapeutics reported $99 million in sales from Casgevy, a therapy for sickle cell and beta thalassemia, in Q3.
- Casgevy is a collaborative effort between CRISPR Therapeutics and Vertex Pharmaceuticals.
- CRISPR's shares fell about 2% in early after-hours trading despite the earnings from Casgevy.
- Alnylam and Vertex Pharmaceuticals are not direct competitors but are both involved in biotech developments.
Articles (12)
The Motley Fool·
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
STAT·
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Financial Times·
Vertex Pharmaceuticals Incorporated, VRTX:BUE summary
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years
Vertex: 3 Key Takeaways for Long-Term Investors